Bandingkan Harga & Kinerja Organon Pharma Indonesia Tbk. (SCPI) vs Satu Visi Putra Tbk. (VISI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Organon Pharma Indonesia Tbk. dan Satu Visi Putra Tbk.: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Satu Visi Putra Tbk. diperdagangkan di Rp1.035 (kapitalisasi pasar 2,97 T, volume 24 jam 3,06 jt). Perbedaan utamanya: Satu Visi Putra Tbk. jauh lebih besar — sekitar 28,4× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| SCPI | VISI | |
|---|---|---|
Kapitalisasi Pasar | 104,4 M | 2,97 T |
Volume | — | 3,06 jt |
Lot | — | 30,57 rb |
Perputaran | — | 3,05 M |
Harga Rata-rata | — | 998,37 |
Nilai Transaksi | — | 3,05 M |
Harga Ekuilibrium Indikatif | — | 1.035 |
Volume Ekuilibrium Indikatif | — | 199 |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →Tentang Satu Visi Putra Tbk.
PT Satu Visi Putra Tbk (the Entity) was established based on Deed No. 16, dated February 14, 2018 of Soeprayitno, S.H., notary in Surabaya. The Entity started its commercial operation in 2018.
Selengkapnya di halaman VISI →
